Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
514G3 in Staphylococcus aureus bacteremia
NCT02357966Phase 2Completed
- Sponsor
- XBiotech Inc.
- Start
- May 2015
- Primary completion
- Dec 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of omodenbamab in Staphylococcus aureus bacteremia (SAB), sponsored by XBiotech Inc. Primary endpoints: Dose-Limiting Toxicities at 30 days and Adverse Events at 30 days. Started May 2015; status: completed.
02
Drugs
omodenbamab
03
Conditions
Staphylococcus aureus bacteremia (SAB)
Beyond the preview
Go deeper on NCT02357966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02357966.